MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Predictive Oncology Net Income 2011-2026 | POAI
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Predictive Oncology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.7 M | -14 M | -25.7 M | -19.7 M | -25.9 M | -19.4 M | -10.1 M | -7.75 M | -6.53 M | -4.79 M | -6.83 M | -9.41 M | -7.42 M | -4.49 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.49 M | -25.9 M | -12.5 M |
Quarterly Net Income Predictive Oncology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -77.7 M | -2.07 M | -2.44 M | - | -3.09 M | -3.18 M | -4.22 M | - | -3.16 M | -3.92 M | -3.42 M | - | -4.06 M | -10.4 M | -3.37 M | - | -5.44 M | -2.57 M | -3.89 M | - | -6.31 M | -3.58 M | -4.53 M | - | -4.01 M | 1.47 M | -3.29 M | - | -2.51 M | -2.37 M | -1.76 M | - | -992 K | -2.54 M | -7.75 M | - | -6.53 M | -6.53 M | -6.53 M | - | -4.79 M | -1.19 M | -226 K | - | -1.12 M | -1.74 M | -1.62 M | - | -3.97 M | -1.18 M | -2.1 M | - | -2.86 M | -2.14 M | -713 K | - | -477 K | -477 K | -4.49 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.47 M | -77.7 M | -4.88 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical instruments industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
19.4 M | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
1.68 B | $ 184.86 | 1.31 % | $ 53.2 B | USA |
 |
Baxter International
BAX
|
-957 M | $ 21.74 | 1.85 % | $ 11.2 B | USA |
 |
Luminex Corporation
LMNX
|
15.2 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-17.6 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
56.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
13.7 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
-24.5 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
223 M | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
292 M | - | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-11.3 M | $ 11.29 | -8.21 % | $ 228 M | USA |
 |
ICU Medical
ICUI
|
732 K | $ 155.85 | 4.08 % | $ 3.84 B | USA |
 |
Alcon
ALC
|
376 M | $ 82.21 | -1.21 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
-11.4 M | $ 32.79 | 1.27 % | $ 1.57 B | USA |
 |
electroCore
ECOR
|
-18.8 M | $ 6.16 | -0.16 % | $ 34 K | USA |
 |
Harvard Bioscience
HBIO
|
-3.42 M | $ 0.58 | -0.56 % | $ 24.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
44 M | $ 92.55 | 0.75 % | $ 2.08 B | USA |
 |
AngioDynamics
ANGO
|
-34 M | $ 11.22 | 0.13 % | $ 458 M | USA |
 |
InfuSystem Holdings
INFU
|
18 K | $ 7.9 | - | $ 163 M | USA |
 |
The Cooper Companies
COO
|
375 M | $ 84.11 | 0.51 % | $ 16.7 B | USA |
 |
Haemonetics Corporation
HAE
|
168 M | $ 61.61 | 1.55 % | $ 3.1 B | USA |
 |
iRhythm Technologies
IRTC
|
-44.6 M | $ 150.56 | -5.24 % | $ 4.82 B | USA |
 |
Isoray
ISR
|
-79.3 M | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
-135 M | $ 119.69 | 2.21 % | $ 5.8 B | USA |
 |
Repro Med Systems
KRMD
|
-13.7 M | $ 4.72 | 0.64 % | $ 215 M | USA |
 |
OraSure Technologies
OSUR
|
-19.5 M | $ 2.76 | -2.47 % | $ 205 M | USA |
 |
Masimo Corporation
MASI
|
-305 M | $ 175.38 | 0.03 % | $ 9.35 B | USA |
 |
Intuitive Surgical
ISRG
|
2.86 B | $ 504.2 | 0.93 % | $ 180 B | USA |
 |
Merit Medical Systems
MMSI
|
120 M | $ 82.25 | 0.5 % | $ 4.79 B | USA |
 |
Microbot Medical
MBOT
|
-10.7 M | $ 2.07 | -3.95 % | $ 21.1 M |  Israel |
 |
Nephros
NEPH
|
-1.58 M | $ 4.14 | 6.43 % | $ 43 M | USA |
 |
NeuroMetrix
NURO
|
-7.81 M | - | 5.05 % | $ 9.02 M | USA |
 |
Milestone Scientific
MLSS
|
-4.71 M | $ 0.26 | -2.04 % | $ 20.7 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
-910 M | $ 12.63 | 0.88 % | $ 2.57 B | USA |
 |
Envista Holdings Corporation
NVST
|
47 M | $ 29.16 | 1.53 % | $ 4.9 B | USA |
 |
Pro-Dex
PDEX
|
8.98 M | $ 39.55 | 1.41 % | $ 130 M | USA |
 |
Pulse Biosciences
PLSE
|
-72.8 M | $ 21.98 | -12.38 % | $ 1.48 B | USA |
 |
Stereotaxis
STXS
|
-20.7 M | $ 2.08 | -0.24 % | $ 168 M | USA |
 |
Repligen Corporation
RGEN
|
35.6 M | $ 136.76 | -0.34 % | $ 7.62 M | USA |
 |
ResMed
RMD
|
779 M | $ 258.04 | 0.68 % | $ 37.7 B | USA |
 |
BioLife Solutions
BLFS
|
-20.2 M | $ 23.17 | -0.26 % | $ 1.07 B | USA |
 |
STERIS plc
STE
|
615 M | $ 250.32 | -0.34 % | $ 24.7 B | USA |
 |
Retractable Technologies
RVP
|
-11.9 M | $ 0.67 | -3.48 % | $ 20.1 M | USA |
 |
STAAR Surgical Company
STAA
|
-20.2 M | $ 17.65 | -1.29 % | $ 867 M | USA |
 |
Teleflex Incorporated
TFX
|
69.7 M | $ 115.88 | 3.65 % | $ 5.43 B | USA |
 |
Utah Medical Products
UTMD
|
4.29 M | $ 67.96 | 2.09 % | $ 247 M | USA |
 |
West Pharmaceutical Services
WST
|
494 M | $ 241.54 | -0.94 % | $ 17.5 B | USA |